Tempus AI, Inc. (NASDAQ:TEM) EVP Sells $45,459.90 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 1,130 shares of Tempus AI stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $40.23, for a total value of $45,459.90. Following the completion of the sale, the executive vice president now directly owns 244,955 shares in the company, valued at $9,854,539.65. This represents a 0.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, December 11th, Andrew Polovin sold 51,504 shares of Tempus AI stock. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $35.54 on Friday. The stock’s 50 day moving average is $51.70. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TEM. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital increased their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently made changes to their positions in the stock. Kovitz Investment Group Partners LLC acquired a new position in Tempus AI in the 3rd quarter valued at $1,367,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the period. Captrust Financial Advisors acquired a new position in Tempus AI in the third quarter valued at $2,726,000. Sigma Planning Corp purchased a new position in Tempus AI during the third quarter worth about $1,323,000. Finally, Dakota Wealth Management acquired a new stake in Tempus AI in the 3rd quarter worth about $1,185,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.